Search - tctmd.com

Displaying 541 - 560 of 8070

Sort: Relevancy | Date

Presentation Cardiovascular Interventions 2024

AGENT DCB: Device and Data

Presenter: Paul S. Teirstein

November 11, 2024

Presentation Cardiovascular Interventions 2024

Transcatheter Tricuspid Replacement or Repair: Matching the Device with the Patient

Presenter: Matthew J. Price

November 11, 2024

News Conference News TCT 2024

Percutaneous Mechanical Aspiration Promising for Right-Heart Infective Endocarditis

Caitlin E. Cox

November 08, 2024

News Daily News

FDA Approves Varipulse Pulsed-Field Ablation System for AF

Michael O'Riordan

November 07, 2024

News Conference News TCT 2024

Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick

Yael L. Maxwell

November 07, 2024

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

L.A. McKeown

November 06, 2024

News Conference News TCT 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Michael O'Riordan

November 06, 2024

News Conference News TCT 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Yael L. Maxwell

November 05, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Conference News TCT 2024

Vascular Closure via Suture/Plug Combo Reduces Complications: ACCESS-TAVI

Caitlin E. Cox

November 04, 2024

News Conference News TCT 2024

PAD Patients’ Views on Decisions and Outcomes Hinge on Sex, Race/Ethnicity: ELEGANCE

L.A. McKeown

November 04, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2024

Shelley Wood

November 01, 2024

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

L.A. McKeown

November 01, 2024

News Conference News TCT 2024

Embolic Protection Benefits Varied by Geography in PROTECTED TAVR

Todd Neale

October 31, 2024

News Conference News TCT 2024

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

Caitlin E. Cox

October 31, 2024

News Conference News TCT 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Michael O'Riordan

October 30, 2024

News Conference News TCT 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

Todd Neale

October 30, 2024

Presentation TCT 2024

CV Event Reduction is the Essential Criterion for Implementing New Device Therapies

Presenter: Ori Ben-Yehuda

October 30, 2024

Presentation TCT 2024

One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial

Presenter: Michael Reardon

October 30, 2024

Presentation TCT 2024

TCT 916: MÉTIS Study: Modification of NEurological Outcome After TAVR UsIng Sentinel Protection Device

Presenter: Tomas Kovarnik

October 30, 2024

Advertisement

AGENT DCB: Device and Data

Transcatheter Tricuspid Replacement or Repair: Matching the Device with the Patient

Percutaneous Mechanical Aspiration Promising for Right-Heart Infective Endocarditis

FDA Approves Varipulse Pulsed-Field Ablation System for AF

Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

Vascular Closure via Suture/Plug Combo Reduces Complications: ACCESS-TAVI

PAD Patients’ Views on Decisions and Outcomes Hinge on Sex, Race/Ethnicity: ELEGANCE

TCTMD’s Top 10 Most Popular Stories for October 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

Embolic Protection Benefits Varied by Geography in PROTECTED TAVR

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

CV Event Reduction is the Essential Criterion for Implementing New Device Therapies

One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial

TCT 916: MÉTIS Study: Modification of NEurological Outcome After TAVR UsIng Sentinel Protection Device

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content